1216941-48-8
1216941-48-8 structure
- Name: paritaprevir
- Chemical Name: paritaprevir
- CAS Number: 1216941-48-8
- Molecular Formula: C40H43N7O7S
- Molecular Weight: 765.87700
- Catalog: Signaling Pathways Anti-infection HCV
- Create Date: 2017-10-03 14:34:07
- Modify Date: 2024-01-08 20:10:09
-
Paritaprevir (ABT-450) is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively.
| Name | paritaprevir |
|---|---|
| Synonyms |
(2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16atetradecahydrocyclopropa(E)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxamide
Veruprevir anhydrous ABT450 |
| Description | Paritaprevir (ABT-450) is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. |
|---|---|
| Related Catalog | |
| Target |
EC50: 1 nM(HCV 1a), 0.21 nM(HCV 1b)[1] |
| In Vitro | Paritaprevir demonstrates in vitro antiviral activity against HCV GT1-4 and GT6 (EC50 range, 0.09 to 19 nM), with an EC50 of 0.09 nM against GT4a[2]. |
| In Vivo | The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections1[1]. |
| References |
| Molecular Formula | C40H43N7O7S |
|---|---|
| Molecular Weight | 765.87700 |
| Exact Mass | 765.29400 |
| PSA | 208.50000 |
| LogP | 6.34660 |
| Storage condition | -20℃ |